Aptevo Therapeutics Inc. Net Income Loss

• Aptevo Therapeutics Inc. showed a decrease of -7.6% in Net Income Loss from 2024 to 2025.
• This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: -$11.02 million | Q2 2015: -$17.72 million | Q3 2015: -$12.68 million | Q4 2015: -$17.90 million | Q1 2016: -$12.89 million | Q2 2016: -$12.84 million | Q3 2016: -$71.74 million | Q4 2016: -$14.95 million | Q1 2017: -$9.95 million | Q2 2017: -$11.19 million | Q3 2017: $37.87 million | Q1 2018: -$13.85 million | Q2 2018: -$13.14 million | Q3 2018: -$12.56 million | Q1 2019: -$12.02 million | Q2 2019: -$13.33 million | Q3 2019: -$6.92 million | Q1 2020: $2.90 million | Q2 2020: -$6.80 million | Q3 2020: -$6.79 million | Q1 2021: -$7.26 million | Q2 2021: -$7.93 million | Q3 2021: -$7.00 million | Q1 2022: -$7.70 million | Q2 2022: $28.01 million | Q3 2022: -$7.64 million | Q1 2023: $2.77 million | Q2 2023: -$7.95 million | Q3 2023: -$6.33 million | Q1 2024: -$6.83 million | Q2 2024: -$5.88 million | Q3 2024: -$5.10 million | Q1 2025: -$6.41 million | Q2 2025: -$6.20 million | Q3 2025: -$7.55 million.
• Over the full 11 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Net Income Loss has grown by 56.2%.
• Historical annual values: Fiscal year 2025: -$25.97 million | Fiscal year 2024: -$24.13 million | Fiscal year 2023: -$17.41 million | Fiscal year 2022: $8.03 million | Fiscal year 2021: -$28.46 million | Fiscal year 2020: -$17.75 million | Fiscal year 2019: -$40.45 million | Fiscal year 2018: -$53.69 million | Fiscal year 2017: $6.97 million | Fiscal year 2016: -$112.42 million | Fiscal year 2015: -$59.32 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026